Literature DB >> 29604596

Submicron emulsion of cinnamaldehyde ameliorates bleomycin-induced idiopathic pulmonary fibrosis via inhibition of inflammation, oxidative stress and epithelial-mesenchymal transition.

Li Yan1, Fan Song1, Hua Li1, Yao Li2, Jie Li1, Qiao-Yan He1, Di Zhang1, Fang Wang1, Meng Zhang1, Hang Zhao1, Tian Feng1, Ying-Yong Zhao3, Si-Wang Wang4.   

Abstract

AIMS: Idiopathic pulmonary fibrosis (IPF) is the most frequent and severe form of idiopathic interstitial pneumonias. The pathogenesis is associated with inflammation and oxidative stress and epithelial-mesenchymal transition (EMT). Cinnamaldehyde exhibits antiinflammatory and antioxidant properties, but its effect on IPF is unknown. The present study is to investigate the anti-fibrotic effect and action mechanism of cinnamaldehyde on IPF.
MATERIALS AND METHODS: IPF was induced by intratracheal bleomycin in mice. Submicron emulsion of cinnamaldehyde was given by intraperitoneal injection once everyday for 7 or 21 continuous days after bleomycin administration. Lung histological and injury indexes were analyzed. The protein expressions of inflammation and oxidative stress as well as EMT markers alpha-smooth muscle actin (α-SMA) and E-cadherin in mice and cultured A549 cells were measured.
RESULTS: Cinnamaldehyde attenuated the bleomycin-induced histological injury, reduced hydroxyproline level and improved pulmonary function by the inhibiting inflammatory cytokines and reactive oxygen species production as well as enhancing total superoxide dismutase activity in bleomycin-induced mice. Cinnamaldehyde also inhibited EMT in both bleomycin-induced mice and TGF-β1-stimulated A549 cells.
CONCLUSIONS: Cinnamaldehyde ameliorated bleomycin-induced IPF via inhibition of inflammation and oxidative stress and EMT.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory; Bleomycin; Cinnamaldehyde; Epithelial-mesenchymal transition; Pulmonary fibrosis

Mesh:

Substances:

Year:  2018        PMID: 29604596     DOI: 10.1016/j.biopha.2018.03.145

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Vitamin D deficiency exacerbates bleomycin-induced pulmonary fibrosis partially through aggravating TGF-β/Smad2/3-mediated epithelial-mesenchymal transition.

Authors:  Se-Ruo Li; Zhu-Xia Tan; Yuan-Hua Chen; Biao Hu; Cheng Zhang; Hua Wang; Hui Zhao; De-Xiang Xu
Journal:  Respir Res       Date:  2019-11-27

2.  Management of BMI Is a Potential New Approach for the Prevention of Idiopathic Pulmonary Fibrosis.

Authors:  Yuchao Ma; Chang Feng; Haibo Tang; Peizhi Deng; Yalan Li; Jie Wang; Shaihong Zhu; Liyong Zhu
Journal:  Front Genet       Date:  2022-03-11       Impact factor: 4.599

Review 3.  The Therapeutic Roles of Cinnamaldehyde against Cardiovascular Diseases.

Authors:  Li Lu; Yuan Xiong; Juan Zhou; Guangji Wang; Bobin Mi; Guohui Liu
Journal:  Oxid Med Cell Longev       Date:  2022-10-08       Impact factor: 7.310

4.  Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems.

Authors:  Sai Balaji Andugulapati; Karthik Gourishetti; Satya Krishna Tirunavalli; Taslim Babru Shaikh; Ramakrishna Sistla
Journal:  Phytomedicine       Date:  2020-08-01       Impact factor: 5.340

5.  Yinchenhao Decoction Alleviates Liver Fibrosis by Regulating Bile Acid Metabolism and TGF-β/Smad/ERK Signalling Pathway.

Authors:  Fei-Fei Cai; Rong Wu; Ya-Nan Song; Ai-Zhen Xiong; Xiao-Le Chen; Meng-Die Yang; Li Yang; Yuanjia Hu; Ming-Yu Sun; Shi-Bing Su
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

6.  Cinnamaldehyde inhibits psoriasis‑like inflammation by suppressing proliferation and inflammatory response of keratinocytes via inhibition of NF‑κB and JNK signaling pathways.

Authors:  Zhenzhen Ding; Jingjing Liu; Huangjing Qian; Lingjian Wu; Mingfen Lv
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.